Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 1/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 9/20 | 0.66 |
| ▸ | MGAM | O43451 | 1/20 | 0.47 |
| ▸ | ODC1 | P11926 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30260469 | 1.00 | HSD17B1 (1.00) | HSD17B1PTPN1MGAMODC1 | |
| SCHEMBL22948232 | 1.00 | HSD17B1 (1.00) | HSD17B1PTPN1MGAMODC1 | |
| SCHEMBL31237827 | 0.84 | PTPN1 (0.73) | HSD17B1PTPN1 | |
| Erybreadin B SCHEMBL29571677 | 0.80 | PTPN1 (1.00) | HSD17B1PTPN1MGAM | |
| Erybreadin B SCHEMBL31237953 | 0.80 | PTPN1 (1.00) | HSD17B1PTPN1MGAM | |
| SCHEMBL30645543 | 0.80 | HSD17B1 (0.66) | HSD17B1PTPN1 | |
| SCHEMBL27724151 | 0.80 | HSD17B1 (0.66) | HSD17B1PTPN1 | |
| SCHEMBL29377397 | 0.79 | PTPN1 (1.00) | HSD17B1PTPN1 | |
| SCHEMBL29384928 | 0.77 | HSD17B1 (0.62) | HSD17B1PTPN1MGAMODC1 | |
| SCHEMBL20960789 | 0.76 | HSD17B1 (0.61) | HSD17B1PTPN1MGAMODC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE | 2023-02-09 | — | — | US | disclosed |
| WO-2021113347-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2021-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044407-A1 | TARGETING MB2 OF THE MYC ONCOGENE AND ITS INTERACTION WITH TRRAP IN CANCER | MYCBP, MYC, TERF2IP | HSD17B1 3576/4885PTPN1 3156/4885MGAM 3473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.